News | January 31, 2022
Dr Reddy’s numbers in line; launches in FY23 likely drivers: ICICI Direct
ICICI Direct analysis of Dr Reddy’s Q3FY22 results
ICICI Direct analysis of Dr Reddy’s Q3FY22 results
Vabysmo is the only injectable eye medicine approved simultaneously in the US for wet AMD and DME, with flexible dosing regimens based on patient need
ICICI Direct’s analysis of Cipla’s Q3FY22 results
Intranasal vaccines are easier to administer in mass immunisation campaigns and help reduce or stop transmission
The management guided for ARV API & formulation demand to be normalised from Q4FY22 and reiterated the aspiration of US $ 1 billion in sales by FY23: ICICI Direct
Company to manufacture drug substance for clinical supply of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou, China
The immunogens being tested in IAVI G002 were developed by scientific teams at IAVI and Scripps Research and will be delivered via Moderna's mRNA technology
The award was given as a result of NASSCOM's meticulous screening process, in which over 700 start-ups were shortlisted as the most promising companies of the year
Dr. Reddy's Laboratories has reported consolidated financial results for the period ended December 31, 2021
The vaccines are currently only authorised for emergency use in the country
Subscribe To Our Newsletter & Stay Updated
